Microbiome-synthesized bioactive compounds, such as short-chain fatty acids, are capable of modulating NF-κB, inflammatory cytokines and T-helper cells to affect MM pathogenesis [37]. This evidence concerns the gene NFKB1 and Miyoshi myopathy.